Minerva Neurosciences NERV
NASDAQ NERV
$4.43 -0.26 (-5.54%)
At close: Sep 4, 2026 · 4:00 PM EDT

Minerva Neurosciences (NERV) Non-Current Assets (2013 - 2026)

Minerva Neurosciences' (NERV) quarterly Non-Current Assets came in at $14.9 million in Q1 2026, little changed YoY from $14.9 million in Q1 2025, and little changed on a QoQ basis from $14.9 million in Q4 2025.

Analysis

Minerva Neurosciences (NERV) Non-Current Assets (2013 - 2026) Analysis & Trends

Minerva Neurosciences (NERV) has 14 years of Non-Current Assets data on file, last reported at $14.9 million in Q1 2026.

  • Quarterly Non-Current Assets changed 0.32% year-over-year to $14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.7 million (changed 0.38% YoY) and the FY2025 annual result came in at $14.9 million, changed 0.04% from the prior year.
  • Non-Current Assets steadied at $14.9 million in Q1 2026, from $14.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $15.1 million in Q3 2025 to a low of $14.9 million in Q4 2025.
  • A 5-year average of $14.9 million and a median of $14.9 million in 2023 frame the typical range for Non-Current Assets.
  • Annual changes were most pronounced in 2022 — Non-Current Assets tumbled 50.5% — and 2025, when it rose 1.32%.
  • Tracing NERV's Non-Current Assets over 5 years: stood at $14.9 million in 2022, then slipped by 0.21% to $14.9 million in 2023, then retreated by 0.15% to $14.9 million in 2024, then retreated by 0.04% to $14.9 million in 2025, then increased by 0.34% to $14.9 million in 2026.
  • The last three Non-Current Assets figures came in at $14.9 million (Q1 2026), $14.9 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 14.88 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 23.28 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 1.96 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 5.15 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 294.93 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.96 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 938.60 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 18.06 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 468.65 Mn
10 Minerva Neurosciences 207.37 Mn 207.37 Mn - 15.36 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 15.36 Mn
Mar 31, 2026 14.92 Mn
Dec 31, 2025 14.87 Mn
Sep 30, 2025 15.07 Mn
Jun 30, 2025 14.87 Mn
Mar 31, 2025 14.87 Mn
Dec 31, 2024 14.87 Mn
Sep 30, 2024 14.88 Mn
Jun 30, 2024 14.88 Mn
Mar 31, 2024 14.89 Mn
Dec 31, 2023 14.90 Mn
Sep 30, 2023 14.91 Mn
Jun 30, 2023 14.91 Mn
Mar 31, 2023 14.92 Mn
Dec 31, 2022 14.93 Mn
Sep 30, 2022 14.92 Mn
Jun 30, 2022 14.92 Mn
Mar 31, 2022 14.92 Mn
Dec 31, 2021 14.92 Mn
Sep 30, 2021 30.12 Mn